Living With MOGAD, Informed and Supported

MOGAD (Myelin Oligodendrocyte Glycoprotein Antibody Disease) is a rare autoimmune condition that, like Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD), causes inflammation and damage to the protective myelin covering of nerves in the brain, spinal cord, and optic nerves. However, MOGAD is a distinct disease with its own biological marker: antibodies that attack a specific protein called myelin oligodendrocyte glycoprotein (MOG). Unlike MS, MOGAD does not typically cause the same pattern of brain lesions seen on MRI, and it often has a better long-term outlook with a lower risk of permanent disability. Unlike NMOSD (which involves antibodies against a different protein, called aquaporin-4), MOGAD tends to respond differently to treatment and has a distinct relapse pattern. A blood test for MOG antibodies, combined with MRI and clinical symptoms, helps doctors distinguish between these three conditions.

MOGAD most commonly causes optic neuritis (inflammation of the optic nerve, leading to eye pain and vision loss), transverse myelitis (inflammation of the spinal cord causing weakness, numbness, or bladder and bowel issues), and in children, a condition called ADEM (acute disseminated encephalomyelitis) which can cause confusion, seizures, or fever alongside neurological symptoms. Symptoms often appear suddenly and can affect one or both eyes, and may occur as a single episode or, in some cases, recur over time.

MOGAD is typically diagnosed and managed by a neurologist, often one who specializes in neuroimmunology or demyelinating diseases. A neuro-ophthalmologist may also be involved if optic neuritis is present, and depending on symptoms, care may include physical therapists, occupational therapists, and other rehabilitation specialists.

Yes. MOGAD is typically treated with high-dose corticosteroids during an acute attack to reduce inflammation, and other therapies such as plasma exchange or IVIG (intravenous immunoglobulin) may be used for more severe episodes. For people who experience relapses, long-term immunotherapy may be recommended to help prevent future attacks. Many people with MOGAD recover substantial function after an episode, especially with prompt treatment, and ongoing research continues to improve understanding of long-term management.

Because MOGAD is rare, connecting with others who understand the condition can make a real difference. Organizations such as The Sumaira Foundation and the Siegel Rare Neuroimmune Association (SRNA) offer education, support groups, and resources specifically for MOGAD patients and families.